Title of article
Biodistribution of PEGylated graphene oxide nanoribbons and their application in cancer chemo-photothermal therapy
Author/Authors
Lu، نويسنده , , Yu-Jen and Lin، نويسنده , , Chih-Wen and Yang، نويسنده , , Hung-Wei and Lin، نويسنده , , Kun-Ju and Wey، نويسنده , , Shiaw-Pyng and Sun، نويسنده , , Chia-Liang and Wei، نويسنده , , Kuo-Chen and Yen، نويسنده , , Tzu-Chen and Lin، نويسنده , , Ching-to Albert Ma، نويسنده , , Chen-Chi M. and Chen، نويسنده , , Jyh-Ping، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2014
Pages
13
From page
83
To page
95
Abstract
To use graphene oxide nanoribbons (GONRs) in combination with chemo-photothermal therapy, we modified GONRs with phospholipid-polyethylene glycol (PL-PEG) to prepare PEGylated GONRs (PL-PEG-GONRs), followed by investigation of the short-term in vivo biodistribution of 99mTc-labeled PL-PEG-GONRs and their excretion in mice. The 99mTc-labeled PL-PEG-GONRs demonstrated a unique biodistribution pattern of rapid accumulation in and excretion from the liver. Moreover, we determined that the PL-PEG-GNORs were excreted from the body through the renal route in urine, and we used hematological analysis to show that the PL-PEG-GNORs were not toxic in vivo. Furthermore, doxorubicin-loaded PL-PEG-GONRs had IC50 values for chemo-photothermal therapy toward U87 glioma cells that were 6.7-fold lower than the IC50 values in traditional chemotherapy. With these advantages, PL-PEG-GONRs could be used as drug nanocarriers to develop an efficient cancer-therapy strategy that would not only improve the efficacy of the therapy, but would also reduce the risk of side effects of the nanocarrier in the body.
Journal title
Carbon
Serial Year
2014
Journal title
Carbon
Record number
1927756
Link To Document